The common direct implications of both obesity and insulin resistance (up to type 2 diabetes) in MS [720] have suggested their combination, i.e., an insulin-centered “diabesity” as a nuclear or main defining pathology of the syndrome [721]. This evidence concerns the gene INS and myeloid sarcoma.